BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 10741278)

  • 1. Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
    Maisey NR; Hill ME; Webb A; Cunningham D; Flux GD; Padhani A; Ott RJ; Norman A; Bishop L
    Eur J Cancer; 2000 Jan; 36(2):200-6. PubMed ID: 10741278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
    Zinzani PL; Zompatori M; Bendandi M; Battista G; Fanti S; Barbieri E; Gherlinzoni F; Rimondi MR; Frezza G; Pisi P; Merla E; Gozzetti A; Canini R; Monetti N; Babini L; Tura S
    Leuk Lymphoma; 1996 Jun; 22(1-2):131-5. PubMed ID: 8724540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
    Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
    Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Naumann R; Vaic A; Beuthien-Baumann B; Bredow J; Kropp J; Kittner T; Franke WG; Ehninger G
    Br J Haematol; 2001 Dec; 115(4):793-800. PubMed ID: 11843811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.
    Dittmann H; Sokler M; Kollmannsberger C; Dohmen BM; Baumann C; Kopp A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Oncol Rep; 2001; 8(6):1393-9. PubMed ID: 11605073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of positron emission tomography (PET) in the management of lymphoma patients.
    Zinzani PL; Magagnoli M; Chierichetti F; Zompatori M; Garraffa G; Bendandi M; Gherlinzoni F; Cellini C; Stefoni V; Ferlin G; Tura S
    Ann Oncol; 1999 Oct; 10(10):1181-4. PubMed ID: 10586334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
    Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
    Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas.
    Mikhaeel NG; Timothy AR; Hain SF; O'Doherty MJ
    Ann Oncol; 2000; 11 Suppl 1():147-50. PubMed ID: 10707798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
    Terasawa T; Nihashi T; Hotta T; Nagai H
    J Nucl Med; 2008 Jan; 49(1):13-21. PubMed ID: 18077527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma.
    Ulusakarya A; Lumbroso J; Casiraghi O; Koscielny S; Vantelon JM; Girinsky T; Tardivon A; Bourhis JH; Dartevelle P; Pico JL; Munck JN
    Leuk Lymphoma; 1999 Nov; 35(5-6):579-86. PubMed ID: 10609795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Belhocine T; Hustinx R; Rigo P; Fillet G
    Ann Oncol; 2003 Jan; 14(1):123-30. PubMed ID: 12488304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of (18)F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma.
    Mody RJ; Bui C; Hutchinson RJ; Frey KA; Shulkin BL
    Leuk Lymphoma; 2007 Apr; 48(4):699-707. PubMed ID: 17454627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.